Module 1: Background on Psilocybin
Module 2: Psilocybin Legality & the Oregon Psilocybin Services Act
Module 3: Research-Investigated Indications
Module 4: Managing Medical Risk in Patients Seeking Psilocybin Therapy
This activity is intended for all providers delivering primary care to adults, and to all health practitioners such as psychiatrists and psychiatric nurse practitioners.
After completing this activity, the participant should be better able to:
President, Psychedelic Medicine Association; Host, Psychedelic Medicine Podcast
Lynn Marie Morski, MD, JD, is president of the Psychedelic Medicine Association and host of the Psychedelic Medicine Podcast. She sits on the advisory boards of VETS, Inc (Veterans Exploring Treatment Solutions), Psychedelics Today, Ketamine Task Force, and Cybin. Dr. Morski received her medical degree from St. Louis University School of Medicine, completed family medicine residency at Mayo Clinic, and did her sports medicine fellowship at the University of Arizona. She later received her law degree from Thomas Jefferson School of Law and is a member of the California Bar.
Non-Mutual funds/Stock Ownership/Stock options:
Chief Clinical Officer, Numinus; Board Member, Psychedelic Medicine Association
Dr. Reid Robison is a board-certified psychiatrist and Chief Clinical Officer at Numinus, and oversees the clinical services, including teaching and training in ketamine-assisted psychotherapy, for the company’s clinics across the US and Canada. He has led over 200 clinical trials in neuropsychiatry, and previously served as coordinating investigator for the MAPS-sponsored MDMA-assisted psychotherapy study of eating disorders. He is currently principal investigator for a number of psychedelic medicine studies with psilocybin, LSD and DMT. As an early adopter and researcher of ketamine in psychiatry, Dr. Robison got his first grant to study ketamine in 2011, and around that time also led a pivotal IV ketamine study for treatment-resistant depression by Janssen. To date, Dr. Robison has guided thousands of ketamine therapy journeys and Spravato dosing sessions, and has worked in ayahuasca retreat settings abroad. Dr. Robison is also an adjunct professor at both the University of Utah and Brigham Young University.
Reid Robison, MD, MBA
Speakers Bureau/Honoraria for non-CME:
Founder, Spirit Pharmacist LLC
Dr. Ben Malcolm earned his bachelor’s degree (BS) in pharmacology at the University of California at Santa Barbara, prior to his Masters in Public Health (MPH) and Doctorate of Pharmacy (PharmD) at Touro University California. He then completed post-graduate residencies in Acute Care at Scripps Mercy Hospital and Psychiatric Pharmacy at the University of California at San Diego Health.
After residency he passed his exam to become Board Certified in Psychiatric Pharmacy (BCPP). He began his career as an Assistant Clinical Professor at Western University of Health Sciences (WUHS), College of Pharmacy before transitioning to his current entrepreneurial role as a Psychopharmacology Consultant, Psychedelic Educator, and Founder of Spirit Pharmacist.
Ben envisions a society in which access to psychedelic drugs in a variety of safe and supported settings is available for purposes of psychospiritual well-being, personal development, ceremonial sacraments, and treatment of mental illness. His focus is on the intersection between psychiatric medications and psychedelic therapies. He has given several Continuing Education presentations to pharmacists and other healthcare professionals as well as published over a dozen articles in peer-reviewed literature relating to psychedelics or psychiatric medications.
His vision guides his clinical and education service-related professional activity.
Non-Mutual funds Stock Ownership/Stock options:
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated.
In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:
If you have questions regarding the certification of this activity, please contact PIM via email at [email protected].
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the Psychedelic Medicine Association. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 2 contact hours. (If applicable, for APRNs, enduring activity)
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2 APA Category 1 CME credits. Approval is valid until April 27, 2024. PAs should only claim credit commensurate with the extent of their participation.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
The purpose of this course is to educate healthcare providers so that when patients ask if psilocybin therapy is appropriate for them, those providers will be able to do an informed risk assessment with the patient.
In order to get clinicians comfortable with having these conversations and doing these assessments, the course covers the basics of psilocybin therapy, the indications for which psilocybin therapy has shown promise in clinical research, the pharmacology of psilocybin (including drug-drug interactions), and the medical risks associated with psilocybin therapy.
This course is intended for healthcare providers who see patients primarily in a primary care setting. The course is intended to teach practitioners how to do a risk assessment based on both mental and physical health factors, so the course is intended for any practitioner who evaluates both for their patients.
Our course is open to clinicians who are members of the Psychedelic Medicine Association, which is open to licensed healthcare providers, healthcare trainees, and students in healthcare-related programs.
The course is self-paced and consists of four modules, each taking approximately 30 minutes to complete. So, the total duration of the course is about two hours resulting in two CME/CE hours.
The course is structured into four modules, each containing lecture slides. There is also a final exam at the end of the course.
Yes, here are the accreditations:
Physician Continuing Medical Education
Continuing Nursing Education
Continuing Physician Assistant Education
The course is available to members of the Psychedelic Medicine Association. The cost of the course is $100.
Yes, upon successfully completing the course and passing the final exam, you will be redirected to a page with instructions for obtaining your certificate through CME University.
No, this course is not meant to provide you with the necessary qualifications to provide psilocybin therapy. It is meant to provide you with the knowledge and tools to manage medical risks associated with psilocybin therapy.
You can enroll by clicking any of the “enroll now” buttons towards the top of this page which will redirect you to a checkout page. If you’re not yet a member of the Psychedelic Medicine Association, you will be prompted to sign up. Once you’ve registered and verified your account, you’ll be emailed an enrollment confirmation with a link to access the course. If you’re having any issues contact support at [email protected].
Once you are a member and have enrolled, you will be emailed a link to access the course which you can return to at any point if you are unable to complete the course in one sitting. You can also access the course content by returning to the course page, where you are now, and logging in using the widget at the top of the page if you aren’t already. Once you’re logged in, you will see the different modules for the course displayed at the top of the page. Click on the module where you left off and you will be redirected to begin the relevant course page. If you’re having any issues contact support at [email protected].
There was a problem reporting this post.
Please confirm you want to block this member.
You will no longer be able to:
Please allow a few minutes for this process to complete.
Use the button for instructions on receiving your CE certificate and listing your practice in our directory of psilocybin-informed clinicians.